Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer?

Person, Anna K.

doi:10.1007/s11904-012-0120-1

Cited by 9 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies conducted concerning this problem do not equivocally show which method of administration of isoniazid is best in considering time. Directly observed 3-month administration once a week of isoniazid plus rifampicin, was at least as effective as a 9-month daily administration of isoniazid, mainly in patients not infected with HIV, and living in countries with low or mediocre morbidity due to tuberculosis [9]. Own study indicated that a centralised time of administration of isoniazid (6 months) was very effective.…”

Section: Discussionmentioning

confidence: 94%

Effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS – retrospective analysis of data from Almaty, Kazakhstan, 2010–2015

Juszkiewicz

Włoszczak-Szubzda

et al. 2020

Ann Agric Environ Med.

View full text Add to dashboard Cite

Introduction. According to data from the National Centre for Prevention and Control of AIDS, in the Republic of Kazakhstan, 45.8% of patients in the symptomatic stages of HIV infection are diagnosed with tuberculosis (TB) which is the cause of death in 36% of patients infected with HIV. Objective. The aim of the study was to conduct a retrospective analysis of the effectiveness of tuberculosis (TB) chemoprophylaxis among people living with HIV in the Republic of Kazakhstan (RK) in Central Asia. Materials and method. A retrospective analysis of patient health status was performed for each of the 648 patients (323 in the study group and 325 in the control group) during 2010-2015. Data from outpatient treatment charts were used concerning each patient infected with HIV observed at AIDS Treatment Centres. From among the 648 patients infected with HIV, 136 were receiving isoniazid in 2010, and 187 in 2011. The control group consisted of 325 people living with HIV (PLW HIV), who did not received isoniazid during observation. Results. The incidence of TB in patients who underwent chemoprophylaxis did not exceed 0.555/ 100,000 population in the first year of observation. Within 5 years, the TB incidence dropped to 0. In the control group, the TB incidence rate during the first year of observation was 3.262/100,000, with a decrease to 0.364 observed in 2015. Cumulated incidence rate in 2011-2015 in the study group accounted for 1.276/100,000. In the control group, the cumulative incidence was 4.3 times higher and accounted for 5.527. A significant difference in the mortality rate due to TB in the study and control groups was observed, the share of deaths due to TB in study group was 21.6%-nearly 3 times lower than in the control group (57.0%). Conclusions. The effectiveness of chemoprophylaxis for TB depends on biomedical, organizational and cultural factors. The presence of HIV co-infections is a special situation. Opposite to the majority of reports, in own study, no drug-resistant forms of tuberculosis were observed in relation with chemoprophylaxis with isoniazid. In the examined population, TB chemoprophylaxis reduced the incidence and cumulative incidence of TB among PLW HIV by 3.4-4.8 times. Isoniazid chemoprophylaxis decreased 4-fold the annual and cumulative mortality due to TB.

show abstract

Section: Discussionmentioning

confidence: 94%

Effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS – retrospective analysis of data from Almaty, Kazakhstan, 2010–2015

Juszkiewicz

Włoszczak-Szubzda

et al. 2020

Ann Agric Environ Med.

View full text Add to dashboard Cite

show abstract

“…Other drugs such as vedolizumab and certolizumab demand more time and even a higher number of patients to have information robust enough to make this kind of correlation. These data are unprecedented in Brazil and show the importance of the request of screening tests for latent tuberculosis over the years and have an increasing observation according to the time of use, since we are facing a high-risk country for this disease, although the disease has low mortality (32)(33)(34)(35)(36) .…”

Section: Discussionmentioning

confidence: 99%

Rate of Infection (Tuberculosis) in Brazilians Ibd Private Patients: Follow-Up 15 Years

CURY,

MICHELETTI

et al. 2024

Arq. Gastroenterol.

View full text Add to dashboard Cite

Background: Latent tuberculosis (LTB) is a condition where the patient is infected with Mycobacterium tuberculosis but does not develop active TB. There’s a possibility of tuberculosis (TB) activation following the introduction of anti-TNFs. Objective: To assess the risk of biological therapy inducing LTB during inflammatory bowel diseases (IBD) treatment over 15 years in a high-risk area in Brazil. Methods: A retrospective study of an IBD patients’ database was carried out in a private reference clinic in Brazil. All patients underwent TST testing and chest X-ray prior to treatment, and once a year after starting it. Patients were classified according to the Montreal stratification and risk factors were considered for developing TB. Results: Among the analyzed factors, age and gender were risk factors for LTB. DC (B2 and P) and UC (E2) patients showed a higher number of LTB cases with statistical significance, what was also observed for adalimumab and infliximab users, compared to other medications, and time of exposure to them favored it significantly. Other factors such as enclosed working environment have been reported as risk. Conclusion: The risk of biological therapy causing LTB is real, so patients with IBD should be continually monitored. This study reveals that the longer the exposure to anti-TNFs, the greater the risk.

show abstract

“…Patients with latent TB infections should be treated prior to starting any immune suppressive regimen. It is also important to test for HIV since this may have treatment implications [11]. …”

Section: Discussionmentioning

confidence: 99%

Oral Tuberculosis: A Rare Manifestation of Disseminated Disease in a Patient with Dermatomyositis on Chronic Corticosteroids

Khateeb

Kang

Capitle

et al. 2016

Case Reports in Medicine

View full text Add to dashboard Cite

Tuberculosis remains one of the leading causes of death around the world despite advancements in diagnostic testing and medical therapies. It commonly affects the lungs, but isolated extra pulmonary clinical manifestations have been reported. Tuberculosis of the oral cavity is exceedingly rare. We present a case of a patient with dermatomyositis on chronic steroid therapy, who presented with tuberculosis involving the tongue as the only clinical manifestation of disseminated disease. Physicians must be aware of extra pulmonary manifestations of tuberculosis in patients at risk, in order to avoid delays in diagnosis and treatment and to prevent further contagion.

show abstract

Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer?

Cited by 9 publications

References 32 publications

Effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS – retrospective analysis of data from Almaty, Kazakhstan, 2010–2015

Effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS – retrospective analysis of data from Almaty, Kazakhstan, 2010–2015

Rate of Infection (Tuberculosis) in Brazilians Ibd Private Patients: Follow-Up 15 Years

Oral Tuberculosis: A Rare Manifestation of Disseminated Disease in a Patient with Dermatomyositis on Chronic Corticosteroids

Contact Info

Product

Resources

About